Eradicating acute myeloid leukemia in a MllPTD/wt:Flt3ITD/wt murine model: a path to novel therapeutic approaches for human disease

Ley, 2013, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia., N Engl J Med, 368, 2059, 10.1056/NEJMoa1301689 Mrózek, 2012, Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia., J Clin Oncol, 30, 4515, 10.1200/JCO.2012.43.4738 Caligiuri, 1998, Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics., Cancer Res, 58, 55 Dorrance, 2006, Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations., J Clin Invest, 116, 2707, 10.1172/JCI25546 Ayton, 2003, Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9., Genes Dev, 17, 2298, 10.1101/gad.1111603 Faber, 2009, HOXA9 is required for survival in human MLL-rearranged acute leukemias., Blood, 113, 2375, 10.1182/blood-2007-09-113597 Whitman, 2008, DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication., Blood, 112, 2013, 10.1182/blood-2008-01-128595 Bernot, Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML [published online ahead of print May 10, 2013]., Leukemia Zhang, 2012, Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells., Blood, 120, 1118, 10.1182/blood-2012-02-412379 Dorrance, 2008, The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele., Blood, 112, 2508, 10.1182/blood-2008-01-134338 Gilliland, 2001, Hematologic malignancies., Curr Opin Hematol, 8, 189, 10.1097/00062752-200107000-00001 Whitman, 2007, Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study., Blood, 109, 5164, 10.1182/blood-2007-01-069831 Yanada, 2005, Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis., Leukemia, 19, 1345, 10.1038/sj.leu.2403838 Lee, 2007, FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia., Cancer Cell, 12, 367, 10.1016/j.ccr.2007.08.031 Zorko, 2012, Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias., Blood, 120, 1130, 10.1182/blood-2012-03-415067 Liu, 2010, Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia., Cancer Cell, 17, 333, 10.1016/j.ccr.2010.03.008 Liu, 2008, Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia., Blood, 111, 2364, 10.1182/blood-2007-08-110171 Blum, 2012, Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia., Blood, 119, 6025, 10.1182/blood-2012-03-413898 Huang, 2013, Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia., Clin Cancer Res, 19, 2355, 10.1158/1078-0432.CCR-12-3191 Garzon, 2009, MicroRNA 29b functions in acute myeloid leukemia., Blood, 114, 5331, 10.1182/blood-2009-03-211938 Mishra, 2012, Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation., Cancer Cell, 22, 645, 10.1016/j.ccr.2012.09.009 Kim, 2012, Short structured RNAs with low GC content are selectively lost during extraction from a small number of cells., Mol Cell, 46, 893, 10.1016/j.molcel.2012.05.036 Garzon, 2009, MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1., Blood, 113, 6411, 10.1182/blood-2008-07-170589 Xiong, 2011, MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML., Br J Haematol, 153, 753, 10.1111/j.1365-2141.2011.08662.x Blum, 2010, Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine., Proc Natl Acad Sci USA, 107, 7473, 10.1073/pnas.1002650107 Cortes, 2004, Phase I study of bortezomib in refractory or relapsed acute leukemias [published correction appears in Clin Cancer Med. 2004;10(22)7787]., Clin Cancer Res, 10, 3371, 10.1158/1078-0432.CCR-03-0508 Attar, 2008, Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia., Clin Cancer Res, 14, 1446, 10.1158/1078-0432.CCR-07-4626 Attar, 2013, Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502., J Clin Oncol, 31, 923, 10.1200/JCO.2012.45.2177 Guzman, 2001, Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells., Blood, 98, 2301, 10.1182/blood.V98.8.2301